Skip to content
  • Home
  • Sectors
    • Financials
    • Healthcare
    • Materials
    • Industrials
    • Energy
    • Information Technology
    • Consumer Staples
    • Utilities
    • Consumer Discretionary
    • Uncategorised
  • News Type
    • Corporate Strategy & Guidance
    • Dividends & Share Buybacks
    • Earnings Reports
    • Industry-Specific News
    • Investor Relations
    • IPO & Public Listings
    • Macroeconomic Impact
    • Mergers & Acquisitions
    • Regulatory News & Compliance
    • Shareholder Updates
    • Stock Price Movements
  • About Us

Latest News

Ausgold Limited (ASX:AUC) Announces $35M Funding for Katanning Gold Project

Orthocell Limited (ASX:OCC) Reports First US Remplirâ„¢ Sales Revenue

Mach7 Technologies Limited (ASX:M7T) Updates FY25 Guidance and Share Buyback

Netwealth Group Limited (ASX:NWL) Achieves Record FUA Net Flows in Q2 2025

Zenith Minerals Limited (ASX:ZNC) Completes A$3.5M Rights Issue

Finbar Group Limited (ASX:FRI) Acquires Palmyra Development Site

Mineral Commodities Ltd (ASX:MRC) Announces Update on Skaland Graphite Sale

West African Resources Limited (ASX:WAF) Announces Q2 Production Update

Biome Australia Limited (ASX:BIO) Announces Record Sales Revenue

Resolution Minerals (ASX:RML) Receives Drilling Permits and Advances Acquisition of Horse Heaven Project

The Capital Club

The Capital Club

The Hub of Australian Finance News

  • Home
  • Sectors
    • Financials
    • Healthcare
    • Materials
    • Industrials
    • Energy
    • Information Technology
    • Consumer Staples
    • Utilities
    • Consumer Discretionary
    • Uncategorised
  • News Type
    • Corporate Strategy & Guidance
    • Dividends & Share Buybacks
    • Earnings Reports
    • Industry-Specific News
    • Investor Relations
    • IPO & Public Listings
    • Macroeconomic Impact
    • Mergers & Acquisitions
    • Regulatory News & Compliance
    • Shareholder Updates
    • Stock Price Movements
  • About Us
Friday, July 11, 2025

Category: ASX-PYC

PYC Therapeutics Limited

PYC Therapeutics (ASX:PYC) Advances PMS Drug Candidate to Clinical Trials
ASX-PYC Healthcare

PYC Therapeutics (ASX:PYC) Advances PMS Drug Candidate to Clinical Trials

ClubAI 27 June 2025 9:48 am

PYC Therapeutics (ASX:PYC) advances its PMS drug candidate, PYC-002, with promising data supporting its progression to clinical trials.

Corporate Strategy & GuidanceIndustry-Specific News
PYC Therapeutics (ASX:PYC) Aligns with FDA on Registrational Trial Design for RP11 Treatment
ASX-PYC Healthcare

PYC Therapeutics (ASX:PYC) Aligns with FDA on Registrational Trial Design for RP11 Treatment

ClubAI 23 June 2025 1:05 pm

PYC Therapeutics (ASX:PYC) aligns with the FDA on registrational trial design for its RP11 treatment, advancing VP-001 to Phase 2/3 studies.

Industry-Specific NewsRegulatory News & Compliance
PYC Therapeutics (ASX:PYC) Receives Approval for Dose Escalation in ADOA Clinical Trial
ASX-PYC Healthcare

PYC Therapeutics (ASX:PYC) Receives Approval for Dose Escalation in ADOA Clinical Trial

ClubAI 11 June 2025 12:04 pm

PYC Therapeutics (ASX:PYC) receives approval to escalate dosing in its ADOA clinical trial, advancing development of its PYC-001 drug candidate.

Industry-Specific NewsRegulatory News & Compliance
PYC Therapeutics (ASX:PYC) Announces Q1 2025 Shareholder Update
ASX-PYC Healthcare

PYC Therapeutics (ASX:PYC) Announces Q1 2025 Shareholder Update

ClubAI 24 April 2025 2:06 pm

PYC Therapeutics (ASX:PYC) extends cash runway to over $200m and advances polycystic kidney disease program in Q1 2025.

Corporate Strategy & GuidanceInvestor RelationsShareholder Updates

Article Categories

  • Consumer Discretionary
  • Consumer Staples
  • Energy
  • Financials
  • Healthcare
  • Industrials
  • Information Technology
  • Materials
  • Real Estate
  • Telecommunication Services
  • Uncategorised
  • Utilities
  • Publishing Policy
  • About Us
  • Author Biography
The Capital Club